FK506

PreclinicalSmall molecule

Astellas

FK506 is one of 72 small molecule programs targeting Liver Transplant. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Focal Segmental GlomerulosclerosisActive, not recruiting

Membranous NephropathyActive, not recruiting

Liver TransplantPreclinical

Active, not recruiting

Focal Segmental GlomerulosclerosisPreclinical

Active, not recruiting

Membranous NephropathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

96 competitors in Liver Transplant

#DrugCompanyPhaseTrials

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

1 2

Darbepoetin

Bayer

Phase 3

1 3

Prothrombin Complex Concentrate

CSL Behring

Phase 3

1 4

Rezzayo

MMundipharma (China) Pharmaceutical Co. Ltd

Phase 3

1 5

Octreotide

Johnson & Johnson

Preclinical

2 6

Lenvima

Eisai

Preclinical

2 7

Myfortic

Novartis

Preclinical

1 8

Beyfortus

BeiGene

Preclinical

1 9

Prostigmin

Merck & Co.

Preclinical

1 10

Cyklokapron

JJ Molner

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Keratoconjunctivitis2 trials

Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Completed· Astellas logo

Astellas·Phase 3·NCT00567762·56 enrolled

Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Completed· Astellas logo

Astellas·Phase 3·NCT00567918·52 enrolled

Allogeneic Stem Cell Transplantation1 trial

Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases

Terminated·—·Phase 1/2·NCT00056979·2 enrolled

Sickle Cell Disease1 trial

Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00034528·2 enrolled

Focal Segmental Glomerulosclerosis1 trial

The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis

Terminated·NNanjing University School of Medicine·N/A·NCT01451489·70 enrolled

Hematologic Disease1 trial

Stem Cell Transplant for Hematologic Diseases

Terminated·—·Phase 1/2·NCT00058825·27 enrolled

6 more indications

Liver Transplant1 trial

Investigation of Pain Incidence After FK506 Immunosuppressive Therapy in Liver Transplantation Patients

Unknown status·—··NCT04559048·300 enrolled

Efficacy and Safety1 trial

To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN

Completed·NNanjing University School of Medicine·N/A·NCT00302549·61 enrolled

Stem Cell Transplantation1 trial

Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H

Terminated·—·Phase 1/2·NCT00048399·40 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

Completed·—·Phase 1/2·NCT00056966·24 enrolled

Membranous Nephropathy1 trial

Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid

Completed·ZZhi-Hong Liu, M.D.·N/A·NCT01161459·100 enrolled

Bone Marrow Transplant1 trial

Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies

Terminated·—·Phase 2·NCT00040417·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for FK506. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FK506 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FK506. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Astellas

FK506

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Keratoconjunctivitis2 trials

Allogeneic Stem Cell Transplantation1 trial

Sickle Cell Disease1 trial

Focal Segmental Glomerulosclerosis1 trial

Hematologic Disease1 trial

Liver Transplant1 trial

Efficacy and Safety1 trial

Stem Cell Transplantation1 trial

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Membranous Nephropathy1 trial

Bone Marrow Transplant1 trial

References

Drug Info

Quick Facts

Related News